‘X4 Pharmaceuticals gets FDA Orphan Drug Designation for Mavorixafor for treatment of Waldenstrom’s Macroglobulinemia’ -TradeHawk, Citing FDA Site
https://twitter.com/TradeHawk/status/1542897334085775360
The Daily Biotech Pulse: FDA Wants Omicron-Targeted COVID-19 Boosters, Provention Bio Clears Hits Hurdle For Diabetes Prevention Drug, Oxford Biomedica, AstraZeneca Strike Vaccine Pact
Here's a roundup of top developments in the biotech space over the last 24 hours:
X4 Pharmaceuticals Granted U.S. Patent Titled ‘Methods for treating cancer’
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=11337969.PN.&OS=PN/11337969&RS=PN/11337969
25 Stocks Moving in Tuesday’s Pre-Market Session
Gainers
BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 136.4% to $1.43 in pre-market trading. BOQI International recently posted a Q1 loss of $0.27 per share.
The Daily Biotech Pulse: Bristol Myers, BridgeBio Ink Oncology Pact, FDA Nod For Lava Therapeutics Blood Cancer Study And More
Here's a roundup of top developments in the biotech space over the last 24 hours:
Stocks That Hit 52-Week Lows On Tuesday
During Tuesday, 581 stocks hit new 52-week lows.
Interesting Highlights From Today's 52-Week Lows
Meta Platforms (NASDAQ:FB) was the biggest company on a market cap basis to set a new 52-week low.
Canaccord Genuity Maintains Buy on X4 Pharmaceuticals, Lowers Price Target to $10
Canaccord Genuity analyst Arlinda Lee maintains X4 Pharmaceuticals (NASDAQ:XFOR) with a Buy and lowers the price target from $20 to $10.